12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga · 05/01 12:05
Gainers
- NanoVibronix (NASDAQ:NAOV) shares rose 68.2% to $4.81 during Thursday's pre-market session. The market value of their outstanding shares is at $3.9 million.
- LogicMark (NASDAQ:LGMK) stock moved upwards by 36.2% to $0.02.
- Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 28.98% to $0.89. The market value of their outstanding shares is at $5.8 million.
- Sera Prognostics (NASDAQ:SERA) stock moved upwards by 11.56% to $3.28. The market value of their outstanding shares is at $123.5 million.
- Acrivon Therapeutics (NASDAQ:ACRV) shares moved upwards by 10.63% to $1.55. The company's market cap stands at $48.5 million.
- Conmed (NYSE:CNMD) stock increased by 10.42% to $54.23. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q1 earnings came out yesterday.
Losers
- Arvinas (NASDAQ:ARVN) stock fell 31.3% to $6.61 during Thursday's pre-market session. The market value of their outstanding shares is at $454.5 million. As per the press release, Q1 earnings came out today.
- Organon (NYSE:OGN) stock decreased by 16.71% to $10.77. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q1 earnings report came out today.
- BioCardia (NASDAQ:BCDA) stock decreased by 14.65% to $2.68. The market value of their outstanding shares is at $12.2 million.
- Psyence Biomedical (NASDAQ:PBM) shares declined by 12.08% to $0.4. The market value of their outstanding shares is at $1.8 million.
- Amicus Therapeutics (NASDAQ:FOLD) stock decreased by 11.72% to $6.78. The market value of their outstanding shares is at $2.0 billion. The company's, Q1 earnings came out today.
- Greenwich LifeSciences (NASDAQ:GLSI) stock fell 10.9% to $9.0. The company's market cap stands at $119.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.